For 4QFY2016, GlaxoSmithKline Pharmaceuticals (GSK)’s sales rose by Rs686cr,
up 11.8% yoy. On the operating front, the gross margin and the EBITDA margin
came in at 55.0% and 17.8% respectively V/s 57.1% and 19.4% during the
corresponding period of the previous year. The reported net profit for the quarter
thus came in at Rs106cr V/s Rs103cr in 4QFY2015, ie a yoy growth of 3.0%. The
Adj. net profit for the quarter came in at Rs95cr V/s Rs107cr in 4QFY2015, a dip of
10.6% yoy. We remain Neutral on the stock.
Results below our expectations: The company posted an unimpressive
performance for 4QFY2016. The company posted sales of Rs686cr (V/s `828cr
expected), a growth of 11.8% yoy. On the operating front, the gross margin and
the EBITDA margin came in at 55.0% and 17.8% respectively V/s 57.1% and
19.4% during the corresponding period of the previous year. The OPM came
lower than our expectations of 19.6%, weighed down by a lower gross margin on
a yoy basis. The reported net profit for the quarter thus came in at Rs106cr V/s
Rs103cr in 4QFY2015, ie a yoy growth of 3.0%. The Adj. net profit for the quarter
came in at Rs95cr V/s Rs107cr in 4QFY2015, a dip of 10.6% yoy.
Outlook and valuation: The company has a strong balance sheet with cash of
~Rs2,000cr, which could be used for future acquisitions or higher dividend
payouts. On the operational front, we expect the company’s net sales to post a
CAGR of 19.0% to Rs3,881cr and EPS to register a mere CAGR of 21.6% to Rs65.3
over FY2016–18E. We remain Neutral on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...